Related Experiment Video
Updated: Jun 14, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells
Lena Kastl1, Iain Brown, Andrew C Schofield
1School of Medicine and Dentistry, College of Life Sciences and Medicine, University of Aberdeen, Medical School, Foresterhill, Aberdeen, AB25 2ZD, UK.
Abstract:
Docetaxel is an effective chemotherapy drug to treat breast cancer but the underlying molecular mechanisms of drug resistance are not fully understood. DNA methylation is an epigenetic event, involved in the control of gene expression, which is known to play an important role in cancer and chemotherapy drug resistance. To investigate the role of DNA methylation in docetaxel resistance in breast cancer we used two human breast cancer cell lines (MCF-7 and MDA-MB-231) that were made resistant to docetaxel. Docetaxel-resistant sub-lines were treated with different concentrations of decitabine. Global methylation and DNA methyltransferase (DNMT) activity was measured using an ELISA-based assay. Quantitative real-time PCR was used to study DNMT gene expression. Cell viability was studied by MTT assay. Global methylation was increased in MCF-7 but not significantly changed in MDA-MB-231 docetaxel-resistant cells. Decreased DNMT activity and decreased DNMT1 and DNMT3b mRNA expression was associated with docetaxel resistance in both cell lines. To investigate how the components of the DNA methylation machinery may contribute towards docetaxel resistance, decitabine (5-aza-2'-deoxycytidine), an inhibitor of DNA methylation, was used. Decitabine treatment decreased global methylation, DNMT activity and DNMT1, DNMT3a and DNMT3b mRNA expression in MDA-MB-231 docetaxel-resistant cells. In contrast, decitabine-treated MCF-7 docetaxel-resistant cells showed increased DNMT1, DNMT3a and DNMT3b mRNA expression indicating a cell line specific effect of decitabine. Decitabine treatment increased resistance in MCF-7 docetaxel-resistant cells and in the parental MCF-7 and MDA-MB231 docetaxel-sensitive cell lines, however, it did not alter response to docetaxel in MDA-MB-231 docetaxel-resistant cells. This study demonstrates that changes in the DNA methylation machinery are associated with resistance to docetaxel in breast cancer cells. The use of epigenetic therapies, as a strategy to overcome drug resistance, needs to be investigated more fully to determine their effectiveness in different cancers and for different chemotherapy drugs.
Insights
Investigating DNA methylation in breast cancer, this study found changes in the DNA methylation machinery are linked to docetaxel resistance. Epigenetic therapies may offer a strategy to overcome this resistance, but require further investigation.
Area of Science:
- Molecular Biology
- Epigenetics
- Cancer Research
Background:
- Docetaxel is a key chemotherapy for breast cancer, but drug resistance mechanisms remain unclear.
- DNA methylation, an epigenetic process regulating gene expression, is implicated in cancer development and chemotherapy resistance.
Purpose of the Study:
- To explore the role of DNA methylation in docetaxel resistance in human breast cancer cell lines.
- To investigate the impact of decitabine, a DNA methylation inhibitor, on docetaxel resistance.
Main Methods:
- Established docetaxel-resistant MCF-7 and MDA-MB-231 breast cancer cell lines.
- Treated cells with decitabine and assessed global methylation, DNA methyltransferase (DNMT) activity, and DNMT gene expression (DNMT1, DNMT3a, DNMT3b) via ELISA and qRT-PCR.
- Evaluated cell viability using MTT assays.
Main Results:
- Docetaxel resistance was associated with decreased DNMT activity and DNMT1/DNMT3b expression in both cell lines.
- Decitabine reduced methylation and DNMT expression in resistant MDA-MB-231 cells but increased DNMT expression in resistant MCF-7 cells.
- Decitabine enhanced docetaxel resistance in MCF-7 cells and sensitive parental lines, but not in resistant MDA-MB-231 cells.
Conclusions:
- Alterations in the DNA methylation machinery correlate with docetaxel resistance in breast cancer.
- The response to decitabine is cell-line specific, suggesting complex interactions in epigenetic regulation of drug resistance.
- Further research into epigenetic therapies is crucial for overcoming chemotherapy resistance in various cancers.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Abnormal Proliferation
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Treatment Resistant Cancers
